Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,361 active trials259 approved drugs3,860 evidence items
- NCIt
- C7062
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07597993 | BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine Therapy(BEYOND) | recruiting | — | 109 | AstraZenecaINDUSTRY | 4 | Sep 23, 2026 | clinicaltrials |
| NCT07631000 | A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer | recruiting | Phase 2 | 37 | Memorial Sloan Kettering Cancer Center |
| 1 |
| Sep 23, 2026 |
| clinicaltrials |
| NCT07661966 | Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade(IIT BLT) | recruiting | N/A | 12 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07708753 | A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers | recruiting | Phase 3 | 460 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07711847 | Personalized Prone Immobilization for Accelerated Partial Breast Radiotherapy(SHIELD) | recruiting | N/A | 30 | HeroSupport SAINDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07800936 | HP007 Monotherapy for Relapsed or Refractory Advanced Solid Tumors | recruiting | Phase 1 | 44 | Parr Biotechnology (Hebei) Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07808086 | Role of Tumor Microbiota in the Response to Neoadjuvant Therapy in Patients Affected by Triple Negative Breast Cancer | recruiting | — | 30 | Istituti Clinici Scientifici Maugeri SpAOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07822919 | A Study of AWT020 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 96 | Anwita BiosciencesINDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07829848 | Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Systemic Therapy | recruiting | N/A | 534 | Fudan UniversityOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07830134 | Cognitive Rehabilitation for Survivors of Childhood Medulloblastoma Using Real Time Hemodynamic Neurofeedback | recruiting | N/A | 40 | St. Jude Children's Research HospitalOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07837739 | Adjuvant EGFR-TKI Therapy After Surgery for EGFR-Mutant High-Risk Stage IA2-IIB NSCLC | recruiting | — | 100 | Tongji HospitalOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT00001595 | An Investigation of Pituitary Tumors and Related Hypothalmic Disorders | recruiting | — | 2,000 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT00923221 | Collection of Blood From Patients With Prostate Cancer | recruiting | — | 1,000 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT01005654 | Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms | recruiting | — | 2,415 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT01087333 | Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment | recruiting | — | 1,263 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT01143480 | Study of the Effect of Innate on the Inflammatory Response to Endotoxin | recruiting | — | 725 | National Institute of Environmental Health Sciences (NIEHS)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT01174121 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | recruiting | Phase 2 | 332 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02471352 | Studies of Dermatologic Diseases Biospecimen Acquisition Protocol | recruiting | — | 700 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02594202 | Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue | recruiting | — | 3,000 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02693535 | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer(TAPUR) | recruiting | Phase 2 | 4,200 | American Society of Clinical OncologyOTHER | 2 | Sep 22, 2026 | clinicaltrials |
| NCT03258567 | Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas | recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03366116 | 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors | recruiting | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03765333 | GETNE Registration of Thyroid Cancer | recruiting | — | 20 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04291651 | UCSF PANC Cyst Registry(UCSF PCR) | recruiting | — | 4,000 | University of California, San FranciscoOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04561206 | Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | recruiting | Phase 2 | 31 | City of Hope Medical CenterOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04671667 | Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 188 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04815525 | The Longterm Risk of Advanced Colorectal Neoplasia After Colonoscopy - A Population-based Cohort Study in Hong Kong(ACNC) | recruiting | — | 5,000 | Chinese University of Hong KongOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04840056 | Prediction of Gastric Cancer in Intestinal Metaplasia and Atrophic Gastritis(GIMA) | recruiting | — | 1,300 | Chinese University of Hong KongOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04855656 | Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors(MYTHIC) | recruiting | Phase 1 | 464 | Debiopharm International SAINDUSTRY | 5 | Sep 22, 2026 | clinicaltrials |
| NCT04994067 | Intra-Operative Radiation Registry | recruiting | — | 460 | Albert Einstein College of MedicineOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05172245 | Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer | recruiting | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT05215548 | Primary Tumor Resection With EGFR TKI for Stage IV NSCLC | recruiting | Phase 2 | 100 | National Taiwan University HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05554406 | Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) | recruiting | Phase 2 | 335 | National Cancer Institute (NCI)NIH | 3 | Sep 22, 2026 | clinicaltrials |
| NCT05555550 | Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG | recruiting | Early Phase 1 | 30 | Children's Hospital of PhiladelphiaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05588128 | Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL | recruiting | — | 350 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05696782 | Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer | recruiting | Phase 2 | 28 | Wake Forest University Health SciencesOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05765812 | A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma | recruiting | Phase 1 / Phase 2 | 116 | Debiopharm International SAINDUSTRY | 3 | Sep 22, 2026 | clinicaltrials |
| NCT06066138 | A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06085833 | ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions(ANGEL) | recruiting | N/A | 2,706 | ARTIDIS AGINDUSTRY | 3 | Sep 22, 2026 | clinicaltrials |
| NCT06103838 | 18F-Fluciclovine PET/CT in Multiple Myeloma | recruiting | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | recruiting | Phase 1 / Phase 2 | 534 | Revolution Medicines, Inc.INDUSTRY | 7 | Sep 22, 2026 | clinicaltrials |
| NCT06202820 | CV CARE: CardioVascular Care in PC Patients | recruiting | N/A | 180 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06317649 | Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) | recruiting | Phase 2 | 147 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT06445062 | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,130 | Revolution Medicines, Inc.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06453044 | Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma | recruiting | Phase 2 | 41 | City of Hope Medical CenterOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06465316 | Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06641908 | Anti-GD2 ADC M3554 in Advanced Solid Tumors | recruiting | Phase 1 | 65 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 6 | Sep 22, 2026 | clinicaltrials |
| NCT06672146 | Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial) | recruiting | Phase 2 | 93 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
Data updated 6 days agoSource updated Sep 23, 2026source: clinicaltrials